

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 October 2017 (26.10.2017)



(10) International Publication Number
WO 2017/183734 A1

(51) International Patent Classification:
C07C 229/50 (2006.01) *A61P 25/24* (2006.01)
A61K 31/196 (2006.01)

(21) International Application Number:
PCT/JP2017/016125

(22) International Filing Date:
18 April 2017 (18.04.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2016-083147 18 April 2016 (18.04.2016) JP

(71) Applicant: TAISHO PHARMACEUTICAL CO., LTD.
[JP/JP]; 24-1, Takada 3-chome, Toshima-ku, Tokyo
1708633 (JP).

(72) Inventors: OTAKE, Norikazu; c/o Taisho Pharmaceuti-
cal Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo
1708633 (JP). HASHIHAYATA, Takashi; c/o Taisho
Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshi-
ma-ku, Tokyo 1708633 (JP). MATSUDA, Yohei; c/o
Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome,
Toshima-ku, Tokyo 1708633 (JP). MASUDA, Seiji; c/o
Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome,
Toshima-ku, Tokyo 1708633 (JP). YAMAUCHI, Yuko; c/
o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome,
Toshima-ku, Tokyo 1708633 (JP).

(74) Agent: ONO, Shinjiro et al.; YUASA AND HARA, Sec-
tion 206, New Ohtemachi Bldg., 2-1, Ohtemachi 2-chome,
Chiyoda-ku, Tokyo 1000004 (JP).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR,


KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))

(54) Title: PRODRUG OF AMINO ACID DERIVATIVE



(57) Abstract: Provided is an amino acid derivative prodrug represent-
ed by general formula (I-A) that is a prodrug form of an amino acid
derivative which is a group 2 metabotropic glutamate receptor antago-
nist, or a pharmaceutically acceptable salt thereof. More specifically, pro-
vided is an amino acid derivative prodrug represented by general for-
mula (I-A) that is a preventive or therapeutic drug for mood disorders
(including depression and bipolar disorder), anxiety disorder, cognitive
disorders, developmental disorders, Alzheimer's disease, Parkinson's dis-
ease, movement disorders associated with muscular rigidity, sleep disor-
ders, Huntington's chorea, eating disorders, drug dependence, epilepsy,
brain infarction, cerebral ischemia, cerebral insufficiency, cerebral ede-
ma, spinal cord disorders, head trauma, inflammation and immune-relat-
ed diseases, and so on.



WO 2017/183734 A1